Another Golden Feather in Prescient’s Hat, PTX-200 Receives Two US Patents

Summary

• After receiving key licenses for OmniCAR platform Prescient has added one new feather in its hat; receives two US patents for PTX-200.
• These patents for PTX-200 (USPTO 15/487,854 and 15/487,843) are a significant addition to strong IP portfolio of Prescient.
• US patents for PTX-200 is another crucial move in developing a robust product pipeline of novel personalised therapies for cancer.
• Despite COVID-19 pandemic induced disruptions, Prescient made progress with its in-house targeted cancer therapy drugs.

Well-known for developing breakthrough targeted and personalised medicines approaches to treat cancer, Prescient Therapeutics Limited (ASX:PTX) has been gaining attention on the back of its recent achievements. Building on this momentum, on 17 June 2020, the company informed that it has received two US patents for PTX-200.

The targeted therapies include two drug candidates PTX-200 and PTX-100 and cellular therapies include CAR-T with OmniCAR platform.

PTX Expands IP Portfolio Covering PTX-200

Prescient disclosed that it has received notices of allowance from the USPTO (the United States Patent and Trademark Office) for two new patents covering its PTX-200 drug candidate for treating leukemia and breast cancer. After receiving the grants, patents are projected to have validity at least by 2025.

The two key patents for PTX-200 (USPTO 15/487,854 and 15/487,843) are significant accompaniment to strong intellectual property (IP) portfolio of Prescient. This will further increase the protection of PTX-200 along with its potential application in combination with several well-known chemotherapies for a variety of cancers that are difficult to treat. This accomplishment strengthens strong IP position of PTX in a unique targeted therapy.

The patents entitled as “Compositions of triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof”.

On this achievement Prescient CEO and Managing Director, Steven Yatomi-Clarke stated-

He further added, the first half of the calendar year 2020 has been enormously exhilarating for the Company. Despite COVID-19 pandemic interruptions, Prescient made progress with its in-house targeted cancer therapy drugs (PTX-100 and PTX-200) and, recently through the exciting OmniCAR platform, and Prescient is at the forefront of the most exciting and promising arena in oncology.

Brief about PTX-200

Let us shed some light on PTX-200-

A novel PH domain inhibitor PTX-200 inhibits Akt pathway, an important tumor survival pathway performing an essential role in the development of several cancers, including ovarian breast cancer, and leukemia.

Unlike other drug candidates that target Akt inhibition that are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a unique mechanism of action that explicitly inhibits Akt pathways without showing any toxicity and being relatively safer.

READ MORE: Mapping Prescient’s PTX-200 Progress

PTX-200 has demonstrated encouraging Phase 2a data for treatment of HER2-negative breast cancer, Phase 1b/2 in relapsed and refractory acute myeloid leukemia (AML) and Phase 1b in ovarian cancer.

The PTX-200 Phase 1b study in patients with relapsed and refractory acute myeloid leukemia continues in the US after it was expanded based on positive clinical data showing a third complete response in a patient with this difficult to treat cancer.

Moreover, scientists are working to discover an optimal dose of PTX-200 in combination with chemotherapy to curtail side effects.

Late last year, the company reported that interim information from a Phase 1b safety study of PTX-200 in women with recurrent or persistent platinum-resistant ovarian cancer demonstrated 80% (overall 12 out of 15) of patients displayed ‘disease control’, with 11 women exhibiting stable disease and one having a partial response.

In December, data from the Phase 2a trial of PTX-200 in 11 women with HER-2 negative breast cancer showed an overall response rate of 91 per cent, with nine of 10 patients being monitored for cancer remaining progression -free, with encouraging ongoing durability of response.

Bottomline

Amid the turmoil, while some companies are going belly up, Prescient’s first half of CY2020 has been immensely exhilarating, initially by gaining complete IP rights in CAR-T collaboration, subsequently by obtaining key licenses for next-generation immunotherapy platform ‘OmniCAR’ and recently with two US patents for PTX-200.

Prescient is moving progressively with a strong product pipeline backed by a robust management team to address the biggest challenges in the most exciting field of oncology.

On 17 June 2020, PTX share rose by 5.4% to A$0.058 (at AEST 01:49 PM) with a market cap of nearly A$22.47 million.

To know more about Prescient Therapeutics Limited, click here.

To stay updated with PTX company activities and announcements, please update your details on their investor centre.